Abstract: Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide having similarity or homology to a tandem repeat peptide sequence found in a natural protein or natural peptide, and/or the polymer of formula (FX1) in some aspects comprises a peptide comprising at least one catechol residue.

Abstract: In an aspect, disclosed herein is a compound characterized by formula (FX1): A1-X1—X2-A2 (FX1); wherein: A1 is a carboxylic acid group, a carboxylate anion, or a carboxylate ester, X1 is a substituted or unsubstituted and saturated or unsaturated C1-C50 aliphatic group; X2 is a linker group selected from the group consisting of a direct bond, an organic group, -0-, —S—, —S(?O)—, —S(?O)2—, —S—S—, —N?, ?N—, —N(H)—, —N?N—N(H)—, —N(H)—N?N—, —N(OH)—, —N(?O)—, and any combination thereof; and A2 is a peptide, the peptide being terlipressin or a substituted or unsubstituted derivative, a substituted or unsubstituted natural or synthetic analogue, a substituted or unsubstituted variant, a substituted or unsubstituted isomer, or a substituted or unsubstituted fragment of terlipressin.

Abstract: In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides as side chain moieties. Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers and brush block copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers.

Abstract: Ordered structures composed of a plurality of self-assembled peptide nucleic acid (PNA) monomers, and processes of generating same are provided. The plurality of PNA monomers includes modified PNA monomers which are N-protected PNA monomers and/or which feature at least one aromatic moiety attached to a backbone, a nucleobase and/or a nucleobase linkage unit of the PNA monomer. Tunable photonic crystals formed of the provided ordered structures, uses thereof and articles-of-manufacturing containing same are also provided.

Abstract: Ordered (e.g., self-assembled) structures, arranged from peptide nucleic acids and/or analogs thereof, are disclosed. The peptide nucleic acids forming the ordered structures comprise from 1 to 10 PNA backbone units, at least one comprising a guanine nucleobase or an analog thereof. Processes of generating the ordered structures, uses thereof and articles-of manufacturing, devices and systems containing same are also disclosed.

Abstract: Ordered structures composed of a plurality of self-assembled peptide nucleic acid (PNA) monomers, and processes of generating same are provided. The plurality of PNA monomers includes modified PNA monomers which are N-protected PNA monomers and/or which feature at least one aromatic moiety attached to a backbone, a nucleobase and/or a nucleobase linkage unit of the PNA monomer. Tunable photonic crystals formed of the provided ordered structures, uses thereof and articles-of-manufacturing containing same are also provided.

Abstract: Ordered (e.g., self-assembled) structures, arranged from peptide nucleic acids and/or analogs thereof, are disclosed. The peptide nucleic acids forming the ordered structures comprise from 1 to 10 PNA backbone units, at least one comprising a guanine nucleobase or an analog thereof. Processes of generating the ordered structures, uses thereof and articles-of manufacturing, devices and systems containing same are also disclosed.

Abstract: Ordered (e.g., self-assembled) structures, arranged from peptide nucleic acids and/or analogs thereof, are disclosed. The peptide nucleic acids forming the ordered structures comprise from 1 to 10 PNA backbone units, at least one comprising a guanine nucleobase or an analog thereof. Processes of generating the ordered structures, uses thereof and articles-of manufacturing, devices and systems containing same are also disclosed.

Abstract: Ordered (e.g., self-assembled) structures, arranged from peptide nucleic acids and/or analogs thereof, are disclosed. The peptide nucleic acids forming the ordered structures comprise from 1 to 10 PNA backbone units, at least one comprising a guanine nucleobase or an analog thereof. Processes of generating the ordered structures, uses thereof and articles-of manufacturing, devices and systems containing same are also disclosed.